Differential accumulation of advanced glycation end products in the course of diabetic retinopathy

Diabetologia

Volumn 42, Issue 6, 1999, Pages 728-736

  Hammes, H P ^a   Alt, A ^a   Niwa, T ^b   Clausen, J T ^c   Bretzel, R G ^a   Brownlee, M ^d   Schleicher, E D ^e  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c NOVO NORDISK A S   (Denmark)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Department for Internal Medicine   (Germany)

Author keywords

Advanced glycation end products; Carboxymethyllysine; Extracellular matrix; Oxidative stress; Retinopathy

Indexed keywords

ANTIBODY; EPITOPE; GLUCOSE; GLYCOSYLATED PROTEIN; IMIDAZOLE DERIVATIVE; LYSINE DERIVATIVE; OXYGEN; PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CASE REPORT; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOT HYBRIDIZATION; EXTRACELLULAR MATRIX; GLIA; GLYCATION; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; MICROVASCULATURE; MUELLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0033028542     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051221     Document Type: Article

References (44)

1. 1. Brownlee M (1994) Glycation and diabetic complications. Diabetes 43: 836-841
2. 2. Bucala R, Cerami A (1992) Advanced glycation: chemistry, biology and implications in diabetes in aging. Adv Pharmacol 23: 1-34
3. 3. Hammes HP, Weiss A, Hess S et al. (1996) Modification of vitronectin by advanced glycation alters functional properties in-vitro and the diabetic retina. Lab Invest 75: 325-338
4. 4. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycation end products in tissue and the biochemical basis of complications. N Engl J Med 318: 1315-1320
5. 5. Eble AS, Thorpe SR, Baynes JW (1983) Nonenzymatic glucosylation and glucose-dependent cross-linking of proteins. J Biol Chem 258: 9506-9512
6. 6. Fu MX, Knecht KJ, Thorpe SR, Baynes JW (1992) The role of oxygen in cross-linking and chemical modifications of collagen by glucose. Diabetes 41: 42-48
7. 7. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complication in individuals with long-standing IDDM. Diabetes 41: 1286-1292
8. 8. Sell DR, Carlson EC, Monnier VM (1993) Differential effects of type 2 (noninsulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetes 40: 190-196
9. 9. Schleicher E, Nerlich A (1996) The role of hyperglycaemia in the development of diabetic complications. Horm Metab Res 28: 367-373
10. 10. Vlassara H, Brownlee M, Cerami A (1985) High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Procl Natl Acad Sci USA 82: 5588-5592
11. 11. Higashi T, Sano H, Saishoji T et al. (1997) The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes 46: 463-472
12. 12. Araki N, Ueno N, Chakraharti B, Morino Y (1992) Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem 267: 10211-10214
13. 13. Monnier VM, Kohn RR, Cerami A (1984) Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 81: 583-587
14. ε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468
15. 15. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M (1991) Aminoguanidine treatment inhibits the development of experimental diabetic nephropathy. Proc Natl Acad Sci USA 88: 11555-11558
16. 16. Ledl F, Schleicher E (1990) New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl 6: 565-594
17. 17. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC et al. (1996) New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 11 [Suppl 5] 41-47
18. 18. Horie K, Miyata T, Maeda K et al. (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100: 2995-3004
19. 19. Niwa T, Katsuzaki T, Miyazaki S et al. (1997) Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99: 1272-1280
20. 20. Niwa T, Katsuzaki T, Ishizaki Y et al. (1997) Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. FEBS Lett 407: 297-302
21. ε-(carboxymethyl)lysine as a degradation product of fructose lysine in glycated protein. J Biol Chem 261: 4889-4894
22. ε-(1-deoxy-D-fructose-1-yl)hippuryl-lysine. Eur J Biochem 210: 729-739
23. ε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) in tissue proteins. Biochemistry 34: 10872-10878
24. 24. Baynes JW (1991) Pespectives in diabetes, role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412
25. 25. Wolff SP, Dean RT (1987) Glucose autooxidation and protein modification. The potential role of iautooxidative glycosylationi in diabetes. Biochem J 245: 243-250
26. 26. Giardino I, Edelstein D, Brownlee M (1994) Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J Clin Invest 94: 110-117
27. 27. Horiuchi S, Araki N, Morino Y (1991) Immunochemical approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common structure. J Biol Chem 266: 7329-7332
28. ε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075-8083
29. 29. Brett J, Schmidt AM, Yan SD et al. (1993) Survey of the distribution of an newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712
30. 30. Miyata T, Hori O, Zhang J et al. (1996) The receptor for advanced glycation end products (RAGE) mediates the interaction of AGE-β2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98: 1088-1094
31. 31. Krook M, Ghosh D, Stromberg R, Carlquist M, Jornvall H (1993) Carboxyethyllysine in a protein: native carbonyl reductase/NADP(+)-dependent prostaglandin dehydrogenase. Proc Natl Acad Sci USA 90: 502-506
32. 32. Neeper M, Schmidt AM, Brett J et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004
33. 33. Mizutani M, Gerhardinger C, Lorenzi M (1998) Müller cell changes in human diabetic retinopathy. Diabetes 47: 445-449
34. 34. Thornally PJ, Westwood M, Lo TW, McLellan AC (1995) Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol 112: 24-31
35. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glyoxidation reactions. J Biol Chem 271: 9982-9986
36. 36. Ballabriga A (1994) Essential fatty acids and human tissue composition. An overview. Acta Paediatr Suppl 402: 63-68
37. 37. Hammes HP, Bartmann A, Engel L, Wülfroth P (1997) Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 40: 629-634
38. 38. Hammes HP, Federoff HJ, Brownlee M (1995) Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1: 527-534
39. 39. Soulis T, Thalass V, Youseff S et al. (1997) Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628
40. 40. Murata T, Nagai R, Ishibashi T, Inomata H, Ikeda K, Horiuchi S (1997) The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40: 764-769
41. 41. Chen H-JC, Cerami A (1993) Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J Carbohydr Chem 12: 731-742
42. 42. Araki A, Glomb MA, Takahashi M, Monnier VM (1998) Determination of dicarbonyl compounds as aminotriazines during the Maillard reaction and in vivo detection in aminoguanidine-treated rats. In: O'Brien J, Nursten HE, Crabbe MJC, Ames JM (eds) The Maillard reaction in foods and medicine. Royal Society of Chemistry, Cambridge, UK, 400 (Abstract)
43. 43. Fu C, Pischetsrieder M, Hofmann M, Yan SF, Stern D, Schmidt AM (1998) Carboxymethyl-lysine advanced glycation endproduct modifications of proteins are ligands for RAGE that activate cell signalling pathways. Circulation 98:1651 (Abstract)
44. 44. Hammes HP, Weiss A, Führer D, Krämer HJ, Papavassilis C, Grimminger F (1996) Acceleration of the experimental diabetic retinopathy in the rat by omega-3 fatty acids. Diabetologia 39: 251-255